Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends

•Now evidence for chemo, immuno and targeted therapy in 3rd line treatment OG cancer.•Sequential treatment approaches are of benefit to a growing minority of patients.•Factors such as PS, prior response and tumour burden may identify potential responders.•Refining predictive biomarkers may further aid in effective patient selection.